Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.
Identifieur interne : 001626 ( Main/Exploration ); précédent : 001625; suivant : 001627Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.
Auteurs : E. Boulanger [France] ; P V Afonso ; Y. Yahiaoui ; H. Adle-Biassette ; J. Gabarre ; F. AgbalikaSource :
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [ 1600-6143 ] ; 2008.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Herpèsvirus humain de type 8 (isolement et purification), Humains (MeSH), Immunosuppresseurs (usage thérapeutique), Infections à Herpesviridae (diagnostic), Infections à Herpesviridae (traitement médicamenteux), Issue fatale (MeSH), Lymphome primitif des séreuses (diagnostic), Lymphome primitif des séreuses (traitement médicamenteux), Lymphome primitif des séreuses (virologie), Mâle (MeSH), Sirolimus (usage thérapeutique), Transplantation rénale (MeSH), Échec thérapeutique (MeSH).
- MESH :
- diagnostic : Infections à Herpesviridae, Lymphome primitif des séreuses.
- isolement et purification : Herpèsvirus humain de type 8.
- traitement médicamenteux : Infections à Herpesviridae, Lymphome primitif des séreuses.
- usage thérapeutique : Immunosuppresseurs, Sirolimus.
- virologie : Lymphome primitif des séreuses.
- Adulte d'âge moyen, Humains, Issue fatale, Mâle, Transplantation rénale, Échec thérapeutique.
English descriptors
- KwdEn :
- Fatal Outcome (MeSH), Herpesviridae Infections (diagnosis), Herpesviridae Infections (drug therapy), Herpesvirus 8, Human (isolation & purification), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Kidney Transplantation (MeSH), Lymphoma, Primary Effusion (diagnosis), Lymphoma, Primary Effusion (drug therapy), Lymphoma, Primary Effusion (virology), Male (MeSH), Middle Aged (MeSH), Sirolimus (therapeutic use), Treatment Failure (MeSH).
- MESH :
- chemical , therapeutic use : Immunosuppressive Agents, Sirolimus.
- diagnosis : Herpesviridae Infections, Lymphoma, Primary Effusion.
- drug therapy : Herpesviridae Infections, Lymphoma, Primary Effusion.
- isolation & purification : Herpesvirus 8, Human.
- virology : Lymphoma, Primary Effusion.
- Fatal Outcome, Humans, Kidney Transplantation, Male, Middle Aged, Treatment Failure.
Abstract
The Akt/mammalian target of rapamycin (mTOR) signaling cascade has been demonstrated to be constitutively activated in several malignancies, including Kaposi sarcoma (KS) and human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma (PEL). In organ transplant recipients, therapeutic change from cyclosporin to the mTOR inhibitor rapamycin can lead to regression of KS lesions. Recent experiments using PEL cell lines and murine xenograft PEL models suggested that rapamycin could inhibit the growth of PEL cells. In the present report, we describe the cases of two HIV-1-negative males of African origin who underwent renal transplantation and developed PEL while receiving rapamycin as immunosuppressive treatment. Both patients were retrospectively found to be HHV-8 seropositive before renal transplantation. The present case report suggests that rapamycin may not protect HHV-8-infected renal transplant recipients from occurrence of PEL or progression of pre-existing PEL.
DOI: 10.1111/j.1600-6143.2007.02110.x
PubMed: 18261181
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.</title><author><name sortKey="Boulanger, E" sort="Boulanger, E" uniqKey="Boulanger E" first="E" last="Boulanger">E. Boulanger</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. emmanuelle.boulanger@sls.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Afonso, P V" sort="Afonso, P V" uniqKey="Afonso P" first="P V" last="Afonso">P V Afonso</name></author><author><name sortKey="Yahiaoui, Y" sort="Yahiaoui, Y" uniqKey="Yahiaoui Y" first="Y" last="Yahiaoui">Y. Yahiaoui</name></author><author><name sortKey="Adle Biassette, H" sort="Adle Biassette, H" uniqKey="Adle Biassette H" first="H" last="Adle-Biassette">H. Adle-Biassette</name></author><author><name sortKey="Gabarre, J" sort="Gabarre, J" uniqKey="Gabarre J" first="J" last="Gabarre">J. Gabarre</name></author><author><name sortKey="Agbalika, F" sort="Agbalika, F" uniqKey="Agbalika F" first="F" last="Agbalika">F. Agbalika</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18261181</idno><idno type="pmid">18261181</idno><idno type="doi">10.1111/j.1600-6143.2007.02110.x</idno><idno type="wicri:Area/Main/Corpus">001638</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001638</idno><idno type="wicri:Area/Main/Curation">001638</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001638</idno><idno type="wicri:Area/Main/Exploration">001638</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.</title><author><name sortKey="Boulanger, E" sort="Boulanger, E" uniqKey="Boulanger E" first="E" last="Boulanger">E. Boulanger</name><affiliation wicri:level="3"><nlm:affiliation>Département d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. emmanuelle.boulanger@sls.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Afonso, P V" sort="Afonso, P V" uniqKey="Afonso P" first="P V" last="Afonso">P V Afonso</name></author><author><name sortKey="Yahiaoui, Y" sort="Yahiaoui, Y" uniqKey="Yahiaoui Y" first="Y" last="Yahiaoui">Y. Yahiaoui</name></author><author><name sortKey="Adle Biassette, H" sort="Adle Biassette, H" uniqKey="Adle Biassette H" first="H" last="Adle-Biassette">H. Adle-Biassette</name></author><author><name sortKey="Gabarre, J" sort="Gabarre, J" uniqKey="Gabarre J" first="J" last="Gabarre">J. Gabarre</name></author><author><name sortKey="Agbalika, F" sort="Agbalika, F" uniqKey="Agbalika F" first="F" last="Agbalika">F. Agbalika</name></author></analytic><series><title level="j">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</title><idno type="eISSN">1600-6143</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Fatal Outcome (MeSH)</term><term>Herpesviridae Infections (diagnosis)</term><term>Herpesviridae Infections (drug therapy)</term><term>Herpesvirus 8, Human (isolation & purification)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Kidney Transplantation (MeSH)</term><term>Lymphoma, Primary Effusion (diagnosis)</term><term>Lymphoma, Primary Effusion (drug therapy)</term><term>Lymphoma, Primary Effusion (virology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Sirolimus (therapeutic use)</term><term>Treatment Failure (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Herpèsvirus humain de type 8 (isolement et purification)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Infections à Herpesviridae (diagnostic)</term><term>Infections à Herpesviridae (traitement médicamenteux)</term><term>Issue fatale (MeSH)</term><term>Lymphome primitif des séreuses (diagnostic)</term><term>Lymphome primitif des séreuses (traitement médicamenteux)</term><term>Lymphome primitif des séreuses (virologie)</term><term>Mâle (MeSH)</term><term>Sirolimus (usage thérapeutique)</term><term>Transplantation rénale (MeSH)</term><term>Échec thérapeutique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Herpesviridae Infections</term><term>Lymphoma, Primary Effusion</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à Herpesviridae</term><term>Lymphome primitif des séreuses</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Herpesviridae Infections</term><term>Lymphoma, Primary Effusion</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Herpesvirus 8, Human</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Herpèsvirus humain de type 8</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Herpesviridae</term><term>Lymphome primitif des séreuses</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunosuppresseurs</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Lymphome primitif des séreuses</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lymphoma, Primary Effusion</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Fatal Outcome</term><term>Humans</term><term>Kidney Transplantation</term><term>Male</term><term>Middle Aged</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Humains</term><term>Issue fatale</term><term>Mâle</term><term>Transplantation rénale</term><term>Échec thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Akt/mammalian target of rapamycin (mTOR) signaling cascade has been demonstrated to be constitutively activated in several malignancies, including Kaposi sarcoma (KS) and human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma (PEL). In organ transplant recipients, therapeutic change from cyclosporin to the mTOR inhibitor rapamycin can lead to regression of KS lesions. Recent experiments using PEL cell lines and murine xenograft PEL models suggested that rapamycin could inhibit the growth of PEL cells. In the present report, we describe the cases of two HIV-1-negative males of African origin who underwent renal transplantation and developed PEL while receiving rapamycin as immunosuppressive treatment. Both patients were retrospectively found to be HHV-8 seropositive before renal transplantation. The present case report suggests that rapamycin may not protect HHV-8-infected renal transplant recipients from occurrence of PEL or progression of pre-existing PEL.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18261181</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-6143</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</Title><ISOAbbreviation>Am J Transplant</ISOAbbreviation></Journal><ArticleTitle>Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.</ArticleTitle><Pagination><MedlinePgn>707-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1600-6143.2007.02110.x</ELocationID><Abstract><AbstractText>The Akt/mammalian target of rapamycin (mTOR) signaling cascade has been demonstrated to be constitutively activated in several malignancies, including Kaposi sarcoma (KS) and human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma (PEL). In organ transplant recipients, therapeutic change from cyclosporin to the mTOR inhibitor rapamycin can lead to regression of KS lesions. Recent experiments using PEL cell lines and murine xenograft PEL models suggested that rapamycin could inhibit the growth of PEL cells. In the present report, we describe the cases of two HIV-1-negative males of African origin who underwent renal transplantation and developed PEL while receiving rapamycin as immunosuppressive treatment. Both patients were retrospectively found to be HHV-8 seropositive before renal transplantation. The present case report suggests that rapamycin may not protect HHV-8-infected renal transplant recipients from occurrence of PEL or progression of pre-existing PEL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boulanger</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Département d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. emmanuelle.boulanger@sls.aphp.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afonso</LastName><ForeName>P V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Yahiaoui</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Adle-Biassette</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gabarre</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Agbalika</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Transplant</MedlineTA><NlmUniqueID>100968638</NlmUniqueID><ISSNLinking>1600-6135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006566" MajorTopicYN="N">Herpesviridae Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019288" MajorTopicYN="Y">Herpesvirus 8, Human</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054685" MajorTopicYN="N">Lymphoma, Primary Effusion</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18261181</ArticleId><ArticleId IdType="pii">AJT2110</ArticleId><ArticleId IdType="doi">10.1111/j.1600-6143.2007.02110.x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Adle Biassette, H" sort="Adle Biassette, H" uniqKey="Adle Biassette H" first="H" last="Adle-Biassette">H. Adle-Biassette</name><name sortKey="Afonso, P V" sort="Afonso, P V" uniqKey="Afonso P" first="P V" last="Afonso">P V Afonso</name><name sortKey="Agbalika, F" sort="Agbalika, F" uniqKey="Agbalika F" first="F" last="Agbalika">F. Agbalika</name><name sortKey="Gabarre, J" sort="Gabarre, J" uniqKey="Gabarre J" first="J" last="Gabarre">J. Gabarre</name><name sortKey="Yahiaoui, Y" sort="Yahiaoui, Y" uniqKey="Yahiaoui Y" first="Y" last="Yahiaoui">Y. Yahiaoui</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Boulanger, E" sort="Boulanger, E" uniqKey="Boulanger E" first="E" last="Boulanger">E. Boulanger</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001626 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001626 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18261181
|texte= Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18261181" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |